# EDGAR Filing Document

**Accession Number:** 0001640251
**File Stem:** 0001104659-25-058273
**Filing Date:** 2025-6
**Character Count:** 15798
**Document Hash:** 413f73c66175886140f3d31bbafe7829
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-058273.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001104659-25-058273

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250610

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250610

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wins Finance Holdings Inc.
- **CENTRAL INDEX KEY:** 0001640251
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-204074
- **FILM NUMBER:** 251038544

**BUSINESS ADDRESS:**
- **STREET 1:** 1177 AVENUE OF THE AMERICAS
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 86 (10) 8225-5118

**MAIL ADDRESS:**
- **STREET 1:** 1177 AVENUE OF THE AMERICAS
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2025**

**Commission File No.: 333-204074**

**WINS FINANCE HOLDINGS INC.**

**1F, Building 1B<br> No. 58 Jianguo Road, Chaoyang District<br> Beijing 100024, People's Republic of China<br> (Address of Principal Executive Offices.)**

**1177 Avenue of the Americas<br> 5th Floor<br> New York, NY 10036<br> 646-694-8538<br> (New York Office)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**Results of Operations and Financial Condition.**

On June 10, 2025, Wins Finance Holdings Inc. (the "Company") released its unaudited and unreviewed financial results for the six months ended December 31, 2024. A copy of the results is attached as Exhibit 99.1.

**Financial Statements and Exhibits.**

Exhibit No. Description <br>[99.1](tm2517252d1_ex99-1.htm) [December 31, 2024 financial results](tm2517252d1_ex99-1.htm)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 10, 2025

---

| | |
|:---|:---|
| **WINS FINANCE HOLDINGS INC.** | **WINS FINANCE HOLDINGS INC.** |
| By: | /s/ Renhui Mu |
| Name: Renhui Mu | Name: Renhui Mu |
| Title: Chief Executive Officer | Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Wins Finance Holdings Inc. Reports Unaudited and Unreviewed Financial Results for the Six Months Ended December 31, 2024**

BEIJING and NEW YORK, May 31, 2025 -- Wins Finance Holdings Inc. ("Wins Finance" or the "Company") (OTC: WINS), an investment and asset management company that provides integrated financing solutions to small and medium enterprises ("SMEs") and sales of medical equipment in China, today announced its unaudited financial results for the first six months ended December 31, 2024.

**Fiscal Six Months Ended December 31, 2024 - Financial and Operational Summary**

 ****

---

| |
|:---|
| Direct financing lease interest income was nil, compared to $0.1 million for the corresponding period ended December 31, 2023. We plan to gradually divest the leasing business. |
| Medical equipment sales was $38.31 million, compared to $33.44 for the corresponding period ended December 31, 2023. This growth is mainly due to more effective sales channels.<br>From July 1, 2024, to December 31, 2024, Wins absorbed some new investments. The company then increased its sales performance requirements and integrated its resources, all of which were used to support the external sales of one of our subsidiaries Shiyue Gongtu. While increasing the sales efforts, we started from the products, integrating the currently authorized medical products with manufacturers for joint sales. After six months of effort, the sales volume increased by 115% in the second half of the year, and the number of new customers increased by 17%, becoming the main driving force for the company's semi-annual report performance growth.<br>Of the $38.31 million, sales by our subsidiary (i) Zhongrui Xukai (Beijing) Technology Co., LTD. ("Xukai") were $0.02 million, mainly selling PET-CT, intraocular lens and molybdenum target to hospitals, (ii) Tianjin Runcheng Medical Technology Co., LTD. ("Runcheng") generated $1.7 million of sales, mainly selling bone nails and accessories to medical device companies, and (iii) Beijing Shiyue Kangtu Medical Equipment Co., LTD ("Shiyue"),generated $36.61 million of sales, mainly selling medical equipment described in more detail below. |
| At present the main focus of our operations is our medical equipment business. We have established a sales agent system covering all of China, and now we are selling PET-CT products (Beijing Ruishi Kang, Beijing Sanuo United, Shanghai United Film), crema ultrasound (Xinbo Medical), B-ultrasound (Shanghai United Film, Samsung), orthopedic consumables (Tianjin Boshuobi) and bone nails to medical device companies. Shiyue mainly sells Philips imaging equipment, Olympus endoscopes, Zeiss microscopes, and Siemens imaging equipment. |

---

On November 25, 2024, Wins Finance Holdings Inc. (the "Company") entered into a share subscription agreement (the "Agreement") with Mr. Jun Fan (the "Investor"). Pursuant to the Agreement, the Investor agreed to purchase 5,600,000 ordinary shares (the "Shares") of the company for an aggregate purchase price of $560,000 ("Purchase Price"). Pursuant to the Agreement, the Investor may require the Company to repurchase the Shares at the Purchase Price within one year of the date of the Agreement. <br>

**Financial Results for the Six Months Ended December 31, 2024**

We currently offer the following principal products and services to our customers, which primarily constitute SMEs: (1) financial leasing and financial advisory and agency services.(2) Medical Equipment Sales.

<u>Medical Equipment Sales.</u>

The income of medical equipment sales was $38.31 million for the six months ended December 31, 2024, as compared to $33.44 for the six months ended December 31, 2023, This growth is mainly due to more effective sales.

<u>Direct financing lease interest income</u>

Direct financing lease interest income generated from payments under direct financing leases with customers was nil for the six months ended December 31, 2024, a decrease of $0.1 million, or 100%, as compared to $0.1 million for the six months ended December 31, 2023. We plan to gradually divest the leasing business.

<u>Non-interest expenses</u>

Non-interest expense was $1.7 million for the six months ended December 31, 2024, as compared to non-interest expense of $1.8 million for the six months ended December 31, 2023.

<u>Income before taxes</u>

Income before taxes was $1.2 million for the six months ended December 31, 2024, an decrease of $0.7 million as compared to loss before taxes of $1.9 million for the six months ended December 31, 2023. The increase was attributable to the high gross profit margin on medical equipment sales. Our net revenue consists of sales revenue from medical equipment and fees on Medical consulting revenue. The increase is mainly due to the increase in Shiyue 's sales revenue. The revenue of Shiyue was $35.09 million.

<u>Net income</u>

Net income was $1.18 million for the six months ended December 31, 2024, an increase of $3.08 million as compared to net loss of $1.9 million for the six months ended December 31, 2023. The increase in net income was mainly due to the increase in Shiyue 's sales revenue, which was $35.09 million. This increase resulted from the growth of sales performance of Shiyue Gongtu in the six-month period.

**Current Outlook**

As the Company's strategic focus shifts to the medical business, we are establishing our own medical research and development and sales team. We believe that our operating experience and enhanced risk management protocols will ultimately help to propel growth once business conditions normalize and our competitive position in our sector continues to strengthen. However, we note that the period-to-period financial results of this sector is affected by the complexity, uncertainties and changes in China's economic conditions as well the regulations governing the industry and can cause fluctuations in our periodic operating and financial results.

**About Wins Finance Holdings Inc.**

Wins Finance Holdings Inc. ("Wins Finance") is focused on medical equipment sales. Our subsidiary Dalian Ruikai Taifu Investment Management Co., LTD. specializes in the medical equipment sales business. Dalian Taifu is responsible administrative licensing, preliminary acceptance and various operating requirements of Shanxi Transformation Comprehensive Reform Health Examination Center, including responsibility for the completion of the medical center, the establishment and improvement of the business systems and staff training. Shiyuegongtu is mainly engaged in medical equipment and consumables sales and medical service consulting.

 **Forward Looking Statements**

This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks are described in the Company's Annual Report on Form 20-F for the year ended June 30, 2021 and in the Company's other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

**Company Contacts:**

Wins Finance Holdings Inc.

1177 Avenue of the Americas

5th Floor

New York, NY 10036

E-mail: info@winsholdings.com

**WINS FINANCE HOLDINGS INC.**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2024** | **Audited**<br>**June 30, 2024** |
| **ASSETS** |  |  |
| Cash | $1448317 | $575152 |
| Accounts receivable net |  | 22636995 |
| Advance to suppliers |  | 18006.908 |
| Interest receivable |  |  |
| Operating lease, right-of-use asset | 127733 | 126388 |
| Property and equipment, net | 54136 | 22521 |
| Due from related party | 633072 | 626207 |
| Other assets | 47833081 | 3485881 |
| Inventory | 878235 | 1599069 |
| Intangible assets | 4104 | 5277 |
| **TOTAL ASSETS** | $**50978718** | $**47084398** |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Liabilities** |  |  |
| Bank loans for capital lease business | $9791611 | $3933853 |
| Contract liabilities |  | 7316569 |
| Accounts payable |  | 19597987 |
| Other current liabilities | 33246025 | 5455302 |
| Deposits from direct financing leases | 1806884 | 1787291 |
| Operating lease liability-current | 111342 | 110135 |
| Long-term loan |  | 2621572 |
| Due to related party | 2964873 | 2932725 |
| Other non-current liability | 1232785 | 1232785 |
| Liabilities of disposal group classified as held for sale |  |  |
| **Total Liabilities** | $**49153520** | **44988219** |
| **Stockholders' Equity** |  |  |
| Common stock (par value $0.0001 per share, 100,000,000 shares authorized; 19,837,642 issued and outstanding at June 30, 2019 and 2018) | $1984 | 1984 |
| Additional paid-in capital | 214048807 | 214026180 |
| Statutory reserve | 4687085 | 5465625 |
| Retained earnings | (197199982) | (199055605) |
| Accumulated other comprehensive loss | (24414812) | (22751325) |
| Minority Interest | 4702116 | 4409320 |
| **Total Stockholders' Equity** | **1825198** | **2096179** |
| **Noncontrolling interests** |  |  |
| **TOTAL LIABILITIES AND EQUITY** | $**50978718** | $**47084398** |

---

**WINS FINANCE HOLDINGS INC.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND**

**COMPREHENSIVE INCOME (LOSS)**

---

| | | |
|:---|:---|:---|
|  | **For six months ended December 31** | **For six months ended December 31** |
|  | <br>**2023** | **2024** |
| **Direct financing lease income** |  |  |
| Direct financing lease interest income | 113225 | $— |
| Interest expense for direct financing lease |  |  |
| Business collaboration fee and commission expenses for leasing projects |  |  |
| Provision for lease payment receivable | (1769197) |  |
| **Net direct financing lease interest income after provision for receivables** | **(1655972)** | $— |
| Consulting revenue | 6589 |  |
| Medical Equipment Sales | 33443241 | 38307975 |
| Cost of sals | (31877619) | (35410996) |
| Revenue,net | 1572211 |  |
| **Net revenue** | **(83761)** | $**2896979** |
| **Non-interest income** |  |  |
| Interest on investment securities-held to maturity |  |  |
| **Total non-interest income** |  | $**-** |
| **Non-interest expense** |  |  |
| Business taxes and surcharges | (5370) | (98297) |
| Salaries and employee charges | (254359) | (12252) |
| Rental expenses | (85488) | (32080) |
| Other operating expenses | (1498398) | (1550868740) |
| **Total non-interest expense** | **(1843615)** | $**(1693497)** |
| **Income before taxes** | **(1927376)** | **1203482** |
| **Income tax expense** | (135050) | (20070) |
| **NET (LOSSES)/INCOME FRROM CONTINUING OPERATION** | **(2062426)** | $**1183412** |
| **Net loss attributable to noncontrolling interests** | (147626836) | $(456352) |
| **Total Net (Losses)/Income** | **(1914800)** | **1639764** |
| **Other comprehensive income (loss)** |  |  |
| **Foreign currency translation adjustment** | (1135396) | (697163) |
| **COMPREHENSIVE (LOSS)/INCOME** | **(3197822)** | $**486249** |
| **Weighted-average ordinary shares outstanding** |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 19.837642 | 25892642 |
| &nbsp;&nbsp;&nbsp;Diluted | 19837642 | 25892642 |
| **Earnings per share** |  |  |
| &nbsp;&nbsp;&nbsp;Basic | (0.1) | $0.06 |
| &nbsp;&nbsp;&nbsp;Diluted | (0.1) | $0.06 |
| &nbsp;&nbsp;&nbsp;From continuing operation | (0.1) | $0.05 |

---